CTCF and breast carcinoma: For instance, high PARP1 mRNA levels are found in tumours as hepatocellular carcinoma, small‐cell lung cancer and breast carcinoma.41, 42, 43 In NB, lncRNA FOXD3‐AS1 was reported to inhibit tumour progression through repressing PARP1‐mediated CTCF activation.44